Search research articles
Contact Us
Filters
Showing results (41-50 of 63) with videos related to
Page
of 7
Sort By:
Breast Cancer Research and Treatment
|
January 1, 1993
Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu
C C Benz, G K Scott, J C Sarup, et al.
British Journal of Cancer
|
April 19, 2014
Long-term survivor characteristics in HER2-positive metastatic breast cancer from registHER
D A Yardley, D Tripathy, A M Brufsky, et al.
Acta Diabetologica
|
December 28, 2013
The inflammatory status score including IL-6, TNF-α, osteopontin, fractalkine, MCP-1 and adiponectin underlies whole-body insulin resistance and hyperglycemia in type 2 diabetes mellitus
G Daniele, R Guardado Mendoza, D Winnier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 24, 1999
Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease
M A Cobleigh, C L Vogel, D Tripathy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 15, 1998
Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment
M D Pegram, A Lipton, D F Hayes, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 6, 2023
Pooled ctDNA analysis of MONALEESA phase III advanced breast cancer trials
F André, F Su, N Solovieff, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 30, 2017
Revisiting the definition of estrogen receptor positivity in HER2-negative primary breast cancer
T Fujii, T Kogawa, W Dong, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 9, 2001
First-line, single-agent Herceptin(R) (trastuzumab) in metastatic breast cancer. a preliminary report
C Vogel, M A. Cobleigh, D Tripathy, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 13, 2001
First-line, single-agent Herceptin(trastuzumab) in metastatic breast cancer: a preliminary report
C Vogel, M A Cobleigh, D Tripathy, et al.
Oncology
|
November 6, 2001
First-line Herceptin monotherapy in metastatic breast cancer
C L Vogel, M A Cobleigh, D Tripathy, et al.
Page
of 7
Search research articles
Search
Showing results (41-50 of 63) with videos related to
Sort By:
Page
of 7
Breast Cancer Research and Treatment
|
January 1, 1993
Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu
C C Benz, G K Scott, J C Sarup, et al.
British Journal of Cancer
|
April 19, 2014
Long-term survivor characteristics in HER2-positive metastatic breast cancer from registHER
D A Yardley, D Tripathy, A M Brufsky, et al.
Acta Diabetologica
|
December 28, 2013
The inflammatory status score including IL-6, TNF-α, osteopontin, fractalkine, MCP-1 and adiponectin underlies whole-body insulin resistance and hyperglycemia in type 2 diabetes mellitus
G Daniele, R Guardado Mendoza, D Winnier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 24, 1999
Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease
M A Cobleigh, C L Vogel, D Tripathy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 15, 1998
Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment
M D Pegram, A Lipton, D F Hayes, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 6, 2023
Pooled ctDNA analysis of MONALEESA phase III advanced breast cancer trials
F André, F Su, N Solovieff, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 30, 2017
Revisiting the definition of estrogen receptor positivity in HER2-negative primary breast cancer
T Fujii, T Kogawa, W Dong, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 9, 2001
First-line, single-agent Herceptin(R) (trastuzumab) in metastatic breast cancer. a preliminary report
C Vogel, M A. Cobleigh, D Tripathy, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 13, 2001
First-line, single-agent Herceptin(trastuzumab) in metastatic breast cancer: a preliminary report
C Vogel, M A Cobleigh, D Tripathy, et al.
Oncology
|
November 6, 2001
First-line Herceptin monotherapy in metastatic breast cancer
C L Vogel, M A Cobleigh, D Tripathy, et al.
Page
of 7